8/14/2019 Drug Discovery (Rajkot)
1/42
Drug Discovery -Drug Discovery - Thought to Pharmacy Self Thought to Pharmacy Self
Dr. Mahesh ChhabriaDr. Mahesh ChhabriaDept. of Medicinal ChemistryDept. of Medicinal ChemistryL. M. College of PharmacyL. M. College of Pharmacy
Ahmedabad 380 009Ahmedabad 380 009
8/14/2019 Drug Discovery (Rajkot)
2/42
Drug DiscoveryDrug Discovery
Discovery of New Chemical Entity (NCE)Discovery of New Chemical Entity (NCE)eliciting desiredeliciting desired
biological responsebiological response
Continuous and ChallengingContinuous and Challenging
Started in 2700 B.C.Started in 2700 B.C.
8/14/2019 Drug Discovery (Rajkot)
3/42
Why ?Why ?
To get better and novel drug.To get better and novel drug. Cancer, AIDS, Viral infections, certain CVSCancer, AIDS, Viral infections, certain CVS
disorders till without proper remedies.disorders till without proper remedies. Overcome certain adverse effects of existingOvercome certain adverse effects of existingdrugs. e.g. NSAIDs GI irrtitation; Hdrugs. e.g. NSAIDs GI irrtitation; H 11--receptor antagonists sedation &receptor antagonists sedation &anticholinergic effectsanticholinergic effects
8/14/2019 Drug Discovery (Rajkot)
4/42
How ?How ?
Traditional (SAR) approach Traditional (SAR) approach Introduced in 1900Introduced in 1900
Rational approachRational approach Introduced in 1960Introduced in 1960
8/14/2019 Drug Discovery (Rajkot)
5/42
Traditional Approach Traditional Approach
Analogue ApproachAnalogue Approach Natural SourceNatural Source
Plant, animal, micro-organisms, marinePlant, animal, micro-organisms, marine Based on serendipity and intuitionBased on serendipity and intuition Based on chemical structure of leadBased on chemical structure of lead
Random screening of large number of Random screening of large number of compoundscompounds Unusual ChemistryUnusual Chemistry
8/14/2019 Drug Discovery (Rajkot)
6/42
Traditional Approach Traditional Approach
1.1. Homolog ApproachHomolog Approach2.2. Molecular FragmentationMolecular Fragmentation3.3. Molecular AdditionMolecular Addition4.4. Isosteric replacementIsosteric replacement
S A RS A R
8/14/2019 Drug Discovery (Rajkot)
7/42
Outcome ..Outcome ..
Traditional Approach Time consuming, Traditional Approach Time consuming,complex, costly, less productivecomplex, costly, less productive
What is the need of time ?What is the need of time ?Efforts on cutting cost DD by reducingEfforts on cutting cost DD by reducingactual number of compounds to beactual number of compounds to besynthesised and screened and stillsynthesised and screened and still
achieving better success rateachieving better success rate Smarter Drug Design Smarter Drug Design
8/14/2019 Drug Discovery (Rajkot)
8/42
Rational ApproachRational Approach
Mechanism based drug designMechanism based drug design Target site / diseased state considered Target site / diseased state considered No importance to chemical structureNo importance to chemical structure Planned synthesis and screeningPlanned synthesis and screening H-bonding, electro negativity values,H-bonding, electro negativity values,
Potential energy, Anchoring sites, Size etc.Potential energy, Anchoring sites, Size etc.are consideredare considered New moleculesNew molecules
8/14/2019 Drug Discovery (Rajkot)
9/42
Drug DesignDrug Design
Research tool for novel drug discoveryResearch tool for novel drug discoveryEfforts to develop new drugs onEfforts to develop new drugs on
rational basis so as to decrease therational basis so as to decrease thetrial and error factors and predict thetrial and error factors and predict the
biological activity before theirbiological activity before their
synthesissynthesis
8/14/2019 Drug Discovery (Rajkot)
10/42
Drug DesignDrug Design (contd.)(contd.)
Points to be considered Points to be considered 1.1. Geometry of the receptorGeometry of the receptor
2.2. Molecular structure of drugMolecular structure of drug3.3. Behavior of the drug in the biophaseBehavior of the drug in the biophase4.4. Drug-receptor interactionDrug-receptor interaction
5.5. Changes in structure on bindingChanges in structure on binding6.6. Resulting biological responseResulting biological response
8/14/2019 Drug Discovery (Rajkot)
11/42
Drug DesignDrug Design (contd.)(contd.)
Multidisciplinary ApproachMultidisciplinary Approach ComputerComputer Medicinal / Organic ChemistryMedicinal / Organic Chemistry Molecular Pharmacology / BiophysicsMolecular Pharmacology / Biophysics Crystallography / SpectroscopyCrystallography / Spectroscopy Biopharmaceutics / PharmacokineticsBiopharmaceutics / Pharmacokinetics
8/14/2019 Drug Discovery (Rajkot)
12/42
Path of Drug DiscoveryPath of Drug DiscoveryTarget IdentificationTarget Identification (Data base)(Data base)
Lead IdentificationLead Identification (Data base, MM)(Data base, MM)
Lead GenerationLead Generation (Data base, Reaction files)(Data base, Reaction files)
Lead ModificationLead Modification (Data base, QSAR)(Data base, QSAR)Lead OptimisationLead Optimisation (QSAR)(QSAR)
Lead MoleculeLead MoleculePreclinical andPreclinical and
Clinical trialsClinical trialsOther formalitiesOther formalities
DRUGDRUG
8/14/2019 Drug Discovery (Rajkot)
13/42
Drug DesignDrug Design (cont.)(cont.)
TOOLSTOOLS
Molecular modelingMolecular modeling
QSARQSAR
8/14/2019 Drug Discovery (Rajkot)
14/42
Molecular ModelingMolecular Modeling
Describes the generation,Describes the generation,manipulation and representation of manipulation and representation of
three dimensional structures of three dimensional structures of molecules and associatedmolecules and associatedphysicochemical propertiesphysicochemical properties
8/14/2019 Drug Discovery (Rajkot)
15/42
MM ProcessMM Process
Define Problem (Data base)Define Problem (Data base)
Build MoleculesBuild Molecules
Visualization & CalculationsVisualization & Calculations
Analyze ResultsAnalyze Results
8/14/2019 Drug Discovery (Rajkot)
16/42
ContCont Quantum Mechanics:Quantum Mechanics:
Calculation of electronic properties implicated on bothCalculation of electronic properties implicated on bothphysical and chemical properties of molecule with theirphysical and chemical properties of molecule with theirbiological environmentbiological environment
Molecular Mechanics:Molecular Mechanics: Molecular mechanics is a method of calculating theMolecular mechanics is a method of calculating thepotential energy of an isolated molecule or system of potential energy of an isolated molecule or system of interfering molecules.interfering molecules.
Molecular Dynamics:Molecular Dynamics: Molecular dynamics simulations can be used to describeMolecular dynamics simulations can be used to describemany kinds of the events involved in drug-receptormany kinds of the events involved in drug-receptor
interactions, including solvation and conformationalinteractions, including solvation and conformationalchanges required for initial complex formationchanges required for initial complex formation
8/14/2019 Drug Discovery (Rajkot)
17/42
Requirements for MMRequirements for MM
Hardware:Hardware: Complicated calculations computer Complicated calculations computer
work station Digital, IBM, Hewlett-work station Digital, IBM, Hewlett-Packard, Silicon GraphicsPackard, Silicon Graphics SoftwareSoftware
As per requirements Modules PCAs per requirements Modules PCbased softwares are Availablebased softwares are Available Accelrys (Discover), Tripos (Sybyl), CCGAccelrys (Discover), Tripos (Sybyl), CCG(MOE)(MOE)
8/14/2019 Drug Discovery (Rajkot)
18/42
Types of MM Types of MM
1.1. Direct type of MMDirect type of MMReceptor or structure based MMReceptor or structure based MM
1.1. Indirect type of MMIndirect type of MMChemical structure based MMChemical structure based MM
DockingDocking
8/14/2019 Drug Discovery (Rajkot)
19/42
Receptor based MMReceptor based MM
8/14/2019 Drug Discovery (Rajkot)
20/42
Indirect type of MMIndirect type of MM
8/14/2019 Drug Discovery (Rajkot)
21/42
8/14/2019 Drug Discovery (Rajkot)
22/42
QSARQSAR
Method to establish quantitativeMethod to establish quantitativerelationship between the descriptorsrelationship between the descriptors
and biological properties of theand biological properties of themoleculesmolecules
8/14/2019 Drug Discovery (Rajkot)
23/42
Why QSAR ?Why QSAR ?
Prediction of the biological activityPrediction of the biological activity Classification of compoundsClassification of compounds Optimisation of biological activityOptimisation of biological activity Lead SearchLead Search Reduction in use of animalsReduction in use of animals Minimise random synthesisMinimise random synthesis Economise new drug discoveryEconomise new drug discovery
8/14/2019 Drug Discovery (Rajkot)
24/42
Various Methods of QSARVarious Methods of QSAR 1. Free Energy Models1. Free Energy Models
Hansch Model LFERHansch Model LFER Martin & Kubynie Model Non LFERMartin & Kubynie Model Non LFER
2. Free Wilson Mathematical model2. Free Wilson Mathematical model 3. Other statistical Models3. Other statistical Models Discriminant AnalysisDiscriminant Analysis
Principal Component AnalysisPrincipal Component Analysis Factor AnalysisFactor Analysis Cluster AnalysisCluster Analysis
Combined Multivariate AnalysisCombined Multivariate Analysis 4. Pattern Recognition4. Pattern Recognition 5. Topological Method5. Topological Method 6. Quantum Mechanical Methods6. Quantum Mechanical Methods
8/14/2019 Drug Discovery (Rajkot)
25/42
Hansch Model -Hansch Model - Random walkRandom walk
KxKx
CC ACAC ResponseResponse
ExtracellularExtracellular Random walkRandom walk Critical reactionCritical reactionPhasePhase sitesite
LL L, StL, St EE L, E,StL, E,St
8/14/2019 Drug Discovery (Rajkot)
26/42
Hansch ModelHansch Model
PrinciplePrincipleB.A. B.A. L,L, E,E, StSt
Linear FormLinear FormLog1/c = alogP + bLog1/c = alogP + b + dEs + c+ dEs + c
log1/Clog1/C
PP
8/14/2019 Drug Discovery (Rajkot)
27/42
Requirements for QSARRequirements for QSAR
Biological Activity DataBiological Activity Data Large range in observed activity (min. 5Large range in observed activity (min. 5
compounds/ parameter)compounds/ parameter) Identical mode of actionIdentical mode of action Concentration in Molar units (g/kg not suitable)Concentration in Molar units (g/kg not suitable) Activity data as function of concentration, i.e,Activity data as function of concentration, i.e,
EDED5050 , I, I5050 , IC, IC5050 , LD, LD5050 , MIC, MBC etc.., MIC, MBC etc.. Activity data in % i.e. protein binding,Activity data in % i.e. protein binding,
metabolism to be transformed to log.metabolism to be transformed to log.
8/14/2019 Drug Discovery (Rajkot)
28/42
Requirements for QSARRequirements for QSAR
Physico-chemical & structuralPhysico-chemical & structuraldiscriptorsdiscriptors
Large range of parameter usedLarge range of parameter used No significant intercorrelation betweenNo significant intercorrelation between
descriptorsdescriptors
About five derivatives per parameterAbout five derivatives per parameter Homogenous distribution in theHomogenous distribution in theparameters used.parameters used.
8/14/2019 Drug Discovery (Rajkot)
29/42
Physicochemical ParametersPhysicochemical Parameters
Electronic ParametersElectronic Parameters Experimental ParametersExperimental Parameters
Ionisation ConstantIonisation Constant Pka,Pka, PkaPka Sigma substituent constantSigma substituent constant ,, -,-, +,+, *,*,
= log K = log K RR/log K /log K HH Tafts constant Tafts constant Inductive substituent constantInductive substituent constant
Spectroscopic Chemical ShiftSpectroscopic Chemical Shift IR, NMRIR, NMR Resonance EffectResonance Effect RR Field EffectField Effect FF Ionisation PotetialIonisation Potetial II
8/14/2019 Drug Discovery (Rajkot)
30/42
8/14/2019 Drug Discovery (Rajkot)
31/42
Physicochemical ParametersPhysicochemical Parameters
Lipophilic ParametersLipophilic Parameters Partition CoefficientPartition Coefficient log P, (logP)log P, (logP) 22
Pi-substituent coefficientPi-substituent coefficient ,, 22
Rm-Chromatographic parameterRm-Chromatographic parameterRm=log[1/Rf-1)Rm=log[1/Rf-1)
Elution time by HPLCElution time by HPLC log Klog Kcapacity factor K = tr-tcapacity factor K = tr-t 00/t/t 00
SolubilitySolubility
8/14/2019 Drug Discovery (Rajkot)
32/42
Physicochemical ParametersPhysicochemical Parameters
Stearic ParameterStearic Parameter Tafts steric substituent constant Tafts steric substituent constant EsEs Vandervals dimensionsVandervals dimensions VVww, r, r vv Molecular connectivityMolecular connectivity
= = cij; Cij = 1/cij; Cij = 1/ ii Parachor [P]Parachor [P]
[P] = V[P] = V = M= M /D/D
Chartons steric constantsChartons steric constants Minimal Steric Difference (MSD)Minimal Steric Difference (MSD) Sterimol parametersSterimol parameters
8/14/2019 Drug Discovery (Rajkot)
33/42
Data generation andData generation and
AnalysisAnalysis QSAR softwareQSAR software
Biological activity & physicochemical parameter value (dataBiological activity & physicochemical parameter value (database or practical)base or practical)
Regression analysis (simple and multipleRegression analysis (simple and multiple )) Multiple correlation coefficient r , qMultiple correlation coefficient r , q F- testF- test Standard error of estimate - sStandard error of estimate - s
EquationEquation Coefficient of parametersCoefficient of parameters Standard errorStandard error T- test T- test Inter correlation between parameterInter correlation between parameter
Prediction of Biological ActivityPrediction of Biological Activity
8/14/2019 Drug Discovery (Rajkot)
34/42
Pharmacokinetics in DrugPharmacokinetics in DrugDiscoveryDiscovery
The activity The activity in vitroin vitro does notdoes notguarantee a sufficientguarantee a sufficient in vivoin vivo effecteffect
~ may be attributed to the PK behavior~ may be attributed to the PK behaviorof drug moleculeof drug moleculePK ProcessesPK Processes
Absorption, Distribution, Metabolism,Absorption, Distribution, Metabolism,EliminationElimination Toxicity Toxicity
8/14/2019 Drug Discovery (Rajkot)
35/42
PharmacokineticsPharmacokinetics
What is Pharmacokinetics ?What is Pharmacokinetics ?A Pharmacokinetic model describesA Pharmacokinetic model describes
the change in the amount of drugthe change in the amount of drug(pharmaco) in the body with time(pharmaco) in the body with time(kinetic)(kinetic)
8/14/2019 Drug Discovery (Rajkot)
36/42
Structural modification and PK Structural modification and PK
PK consequences expected as a result of PK consequences expected as a result of structural modifications in drugstructural modifications in drug
moleculemolecule1.1. Absorption rateAbsorption rate2.2. Volume of distributionVolume of distribution3.3. Metabolism rateMetabolism rate4.4. Affinity constant for binding to serum proteinsAffinity constant for binding to serum proteins5.5. Rate and type of eliminationRate and type of elimination
8/14/2019 Drug Discovery (Rajkot)
37/42
To estimate the influence of small To estimate the influence of smallstructural changes on PKs of a drug can bestructural changes on PKs of a drug can becorrelated with the change in physico-correlated with the change in physico-chemical parameters.chemical parameters.
Quantitative estimation of this correlationQuantitative estimation of this correlationcan be obtained bycan be obtained by
QSPRQSPR
8/14/2019 Drug Discovery (Rajkot)
38/42
QSPRQSPR (Quantitative Structure Pharmacokinetic(Quantitative Structure PharmacokineticRelationship)Relationship)
PK PK L,L, E,E, StSt
PK parametersPK parameters1. Absorption rate constant; Ka1. Absorption rate constant; Ka2. Rate constants of metabolism; Km2. Rate constants of metabolism; Km3. Rate constant of elimination; Kel3. Rate constant of elimination; Kel4. Volume of distribution Vd4. Volume of distribution Vd5. Degree of binding to Plasma proteins5. Degree of binding to Plasma proteins
8/14/2019 Drug Discovery (Rajkot)
39/42
Advantages of QSAR/QSPRAdvantages of QSAR/QSPR
Help to understand the forces underlyingHelp to understand the forces underlyingthe drug action without knowing thethe drug action without knowing thestructure of receptor involved.structure of receptor involved.
Help to understand factors involved inHelp to understand factors involved intransport, metabolism and excretion of transport, metabolism and excretion of drugs.drugs.
It helps in predicting more potent drugsIt helps in predicting more potent drugswithout synthesizing them. (reduce timewithout synthesizing them. (reduce timeand cost)and cost)
8/14/2019 Drug Discovery (Rajkot)
40/42
Disadvantages of Disadvantages of
QSAR/QSPRQSAR/QSPR Insufficient number of compounds andInsufficient number of compounds and
unsatisfactory biological data may lead tounsatisfactory biological data may lead tountrue conclusionsuntrue conclusions
Intercorrelation between two parametersIntercorrelation between two parametersneed to be eliminated.need to be eliminated. Useful for refining a series and not for theUseful for refining a series and not for the
de novode novo research.research. Static and not a dynamic model (2D & notStatic and not a dynamic model (2D & not
3D) 3D-QSAR3D) 3D-QSAR
8/14/2019 Drug Discovery (Rajkot)
41/42
Important books forImportant books for
ReferenceReference Comprehensive Medicinal Chemistry, Vol. 4, ed.Comprehensive Medicinal Chemistry, Vol. 4, ed.
C. A. Ramsden, Pragmon Press.C. A. Ramsden, Pragmon Press. Drug Design Vol. 1, ed., E. J. Ariens, AcademicDrug Design Vol. 1, ed., E. J. Ariens, Academic
Press, New York.Press, New York. Bergers Medicinal Chemistry and DrugBergers Medicinal Chemistry and DrugDiscovery, Vol. 1, ed. M. E. Wolff, WilleyDiscovery, Vol. 1, ed. M. E. Wolff, Willeyinterscience Publicationinterscience Publication
Quantitative Drug Design by Y. C. Martin,Quantitative Drug Design by Y. C. Martin,Marcel Dekker Inc., New York.Marcel Dekker Inc., New York.
Journal of Medicinal Chemistry, ACS Publication Journal of Medicinal Chemistry, ACS Publication
8/14/2019 Drug Discovery (Rajkot)
42/42
Thank YouThank You
Top Related